Cite

HARVARD Citation

    Berthon, C. et al. (2016). Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study. Lancet. 3 (4), pp. e186-e195. [Online]. 
  
Back to record